Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration
2004-001453-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2004
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab and verteporfin in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by Novartis. Primary endpoints: Incidence of severe vision loss and Safety of combined treatment. Started Oct 2004; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2004-001453-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001453-28.